Health equity and personalized medicine share a common goal: tailoring care to the needs of each individual. In this interview, Dr. Octavia Peck Palmer from the University of Pittsburgh Medical Center, immediate past president of ADLM, explains how diversity is foundational to advancing clinical science and improving patient outcomes.

After nearly dying from a mysterious disease during medical school, Dr. David Fajgenbaum dedicated his career to breaking down barriers in biomedical research. Fajgenbaum is now an associate professor of medicine at the University of Pennsylvania and cofounder of Every Cure. In this conversation, we discuss his personal diagnostic journey and the errors and delays he encountered along the way. We also explore why academic medicine needs to go beyond generating disparate pieces of scientific knowledge and instead turn that information into nodes on a network that spans specialty silos to speed the discovery of effective treatments.

Paul Epner’s more than four-decade career started at Abbott Diagnostics and has involved collaboration with the CDC and a tenure as president of the Clinical Laboratory Management Association (CLMA). He now serves as CEO of the Society to Improve Diagnosis in Medicine (SIDM). Throughout his career, Epner has been a powerful advocate for the role of laboratory professionals. In our special Lab Week interview, we discuss why diagnosis is a team sport, how cross-disciplinary collaboration is fundamental to the critical impact of laboratory medicine, and the overall quality of medical care.

Every specimen represents a potential mystery, and laboratory professionals often play the role of detectives. For the 2025 Lab Week episode of LabMind, Amanda Openshaw, a genetic counselor at ARUP, shares examples illustrating the importance of good investigative work in the laboratory to discover accurate diagnoses.

Why hasn’t there been more progress in developing therapies for Alzheimer’s disease and related forms of dementia? One reason has been the lack of specific laboratory tests that can properly diagnose and characterize these diseases. In this interview, Dr. Qinwen Mao from the University of Utah describes how her research team is helping to bring new blood and cerebrospinal fluid biomarkers into clinical practice to step up the fight against these devastating diseases.

As laboratory professionals, we may think we have a good understanding of how physicians use our services. But how often do we ask them for practical feedback? In this interview, family physician Dr. Keith Elkins shares his perspectives on what clinical laboratories and pathologists do well, and what opportunities they may be overlooking to better support frontline clinical care.

Many people in the healthcare profession know that clinical laboratories are under more rigorous regulatory scrutiny than just about any other area of medicine. What they may not know is that the New York State Department of Health (NY DOH) was the pioneer in laboratory regulation, starting long before the implementation of either the FDA Medical Device Amendments or the Clinical Laboratory Improvement Amendments (CLIA) of 1988. In this interview, Beverly Rauch, MS, director of the NY DOH’s Clinical Laboratory Evaluation Program (NY CLEP), describes its process for granting permits, inspecting laboratories, and approving assays, and what the new FDA LDT rule might mean for the program.

In this age of ChatGPT, artificial intelligence (AI), and machine learning, laboratory professionals might think they need to be experts in sophisticated new technology to glean insights from laboratory data. But as ARUP’s medical director of operational informatics Dr. Jenna Rychert points out in this interview, data analysis doesn’t always have to be complicated to provide meaningful value.

Anatomic pathology is on the verge of its biggest technologic shift in over a century. Making a smooth transition will require leadership to pay as much attention to the human impact as to the technology itself. In this discussion, Dr. Suzanne Dintzis from the University of Washington explains why hospital and department leaders will need to partner with front-line laboratory professionals and pathologists who perform the day-to-day work.

As of September 2024, there remains enormous uncertainty about the FDA’s final rule on laboratory-developed tests (LDTs). Will it hold up in court? Which tests are subject to which requirements? How can laboratories best prepare? In this interview, Dr. Jonathan Genzen, ARUP’s chief medical officer and senior director of governmental affairs, responds to questions sent in by members of the laboratory community.